Sertraline 200 MG Oral Capsule — RxCUI 251201
RxNorm drug concept · Semantic clinical drug
RxCUI 251201
Semantic clinical drug · SCD
● Current RxNorm concept 18 FDA products
18 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI251201
Official nameSertraline 200 MG Oral Capsule
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known assertraline 200 MG (as sertraline HCl 224 MG) Oral Capsule
FDA products mapped18
Package NDCs mapped18
Reported Medicaid activity (SDUD)77,466 prescriptions · 40 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Sertraline: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Most people don't feel the full benefit right away — sertraline typically takes several weeks to build up to steady levels in your body. Some people notice small improvements in sl...
- How long does it take for sertraline to start working?
- You should be cautious. Sertraline affects the blood's ability to clot, and combining it with aspirin, ibuprofen, naproxen, or other anti-inflammatory pain relievers raises your ri...
- Is it okay to take sertraline with ibuprofen or aspirin?
🕸️ Concept Web — How Sertraline 200 MG Oral Capsule Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Sertraline 200 MG Oral Capsule
RxCUI 251201 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Sertraline
36437IN
-
Sertraline
-
Dose forms 6
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Sertraline Oral Capsule
373867SCDF -
Sertraline Oral Product
1158194SCDG -
Sertraline Pill
1158195SCDG -
Oral Capsule
316965DF -
Oral Product
1151131DFG -
Pill
1151133DFG
-
Sertraline Oral Capsule
-
Clinical & branded drugs 1
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Sertraline 200 MG
334494SCDC
-
Sertraline 200 MG
Showing up to 8 concepts per family — 8 of 8 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Sertraline 200 MG
SCDC · 334494 -
Sertraline Oral Capsule
SCDF · 373867 -
Sertraline Oral Product
SCDG · 1158194 -
Sertraline Pill
SCDG · 1158195
📦 FDA Products & Package NDCs
18 products · 18 package NDCs
18 package NDCs map to RxCUI 251201 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 47781-0951-30 | 30 CAPSULE in 1 BOTTLE (47781-951-30) | sertraline hydrochloride | Alvogen, Inc. | 2025-09-22 |
| 47781-0962-30 | 30 CAPSULE in 1 BOTTLE (47781-962-30) | sertraline hydrochloride | Alvogen, Inc. | 2025-09-22 |
| 52427-0664-30 | 30 CAPSULE in 1 BOTTLE (52427-664-30) | sertraline HCl | Almatica Pharma LLC | 2021-11-01 |
| 52427-0672-30 | 30 CAPSULE in 1 BOTTLE (52427-672-30) | sertraline HCl | Almatica Pharma LLC | 2021-11-01 |
| 69097-0438-02 | 30 CAPSULE in 1 BOTTLE (69097-438-02) | Sertraline Hydrochloride | Cipla USA Inc. | 2025-07-17 |
| 69097-0451-02 | 30 CAPSULE in 1 BOTTLE (69097-451-02) | Sertraline Hydrochloride | Cipla USA Inc. | 2025-07-17 |
| 69238-2789-01 | 30 CAPSULE in 1 BOTTLE (69238-2789-1) | Sertraline HCl | Amneal Pharmaceuticals NY LLC | 2026-02-02 |
| 69238-2791-01 | 30 CAPSULE in 1 BOTTLE (69238-2791-1) | Sertraline HCl | Amneal Pharmaceuticals NY LLC | 2026-02-02 |
| 70377-0128-11 | 30 CAPSULE in 1 BOTTLE (70377-128-11) | Sertraline HCl | Biocon Pharma Inc. | 2026-01-30 |
| 70377-0129-11 | 30 CAPSULE in 1 BOTTLE (70377-129-11) | Sertraline HCl | Biocon Pharma Inc. | 2026-01-30 |
| 70710-1948-03 | 30 CAPSULE in 1 BOTTLE (70710-1948-3) | Sertraline Hydrochloride | Zydus Pharmaceuticals (USA) Inc. | 2026-01-29 |
| 70710-1949-03 | 30 CAPSULE in 1 BOTTLE (70710-1949-3) | Sertraline Hydrochloride | Zydus Pharmaceuticals (USA) Inc. | 2026-01-29 |
| 70771-1913-03 | 30 CAPSULE in 1 BOTTLE (70771-1913-3) | Sertraline Hydrochloride | Zydus Lifesciences Limited | 2026-01-29 |
| 70771-1914-03 | 30 CAPSULE in 1 BOTTLE (70771-1914-3) | Sertraline Hydrochloride | Zydus Lifesciences Limited | 2026-01-29 |
| 70954-0899-10 | 30 CAPSULE in 1 BOTTLE (70954-899-10) | Sertraline Hydrochloride | ANI Pharmaceuticals, Inc. | 2026-01-20 |
| 70954-0900-10 | 30 CAPSULE in 1 BOTTLE (70954-900-10) | Sertraline Hydrochloride | ANI Pharmaceuticals, Inc. | 2026-01-20 |
| 75907-0310-30 | 30 CAPSULE in 1 BOTTLE (75907-310-30) | Sertraline Hydrochloride | Dr. Reddy's Laboratories Inc. | 2026-01-15 |
| 75907-0311-30 | 30 CAPSULE in 1 BOTTLE (75907-311-30) | Sertraline Hydrochloride | Dr. Reddy's Laboratories Inc. | 2026-01-15 |
Observed labelers:
Almatica Pharma LLC (2) ·
Alvogen, Inc. (2) ·
Amneal Pharmaceuticals NY LLC (2) ·
ANI Pharmaceuticals, Inc. (2) ·
Biocon Pharma Inc. (2) ·
Cipla USA Inc. (2)
· +3 more — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.